Lates News

Every AI Express, Huaxia An Securities released a research report on May 4th, giving a buy rating to Shengxiang Biotechnology (688289.SH). The main reasons for the rating include: 1) increasing penetration rate of respiratory products, expected to maintain high-speed growth; 2) steady progress in mergers and acquisitions, expanding the company's business scope; 3) continuous improvement in cost ratio, profitability maintaining an upward trend. (Daily Economic News)